

ORIGINAL

## [Translated article] Cross-Cultural Validation of the RosaQoL Scale in Spanish Language

M. Salleras Redonnet<sup>a,\*</sup>, J. del Pozo Losada<sup>b</sup>, M. Ribera Pibernat<sup>c</sup>

<sup>a</sup> Servicio de Dermatología, Hospital Universitario Sagrat Cor, Barcelona, Spain

<sup>b</sup> Servicio de Dermatología, Hospital Universitario, A Coruña, Spain

<sup>c</sup> Servicio de Dermatología, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain

Received 21 December 2023; accepted 12 February 2024

### KEYWORDS

Quality of life;  
Rosacea;  
Scale;  
Questionnaire;  
Validation and  
cross-cultural  
adaptation

### Abstract

**Introduction:** Rosacea is a chronic disease negatively impacting the patients' quality of life and mental health. The Rosacea Quality of Life (RosaQoL) scale could be a useful tool to monitor patients while on therapy vs rosacea, as it measures the impact on quality of life and helps individualize treatment to meet the patients' needs. RosaQoL is a validated scale that can be completed within a few minutes.

**Materials and methods:** The original scale was translated and back translated by 2 native translators, with input from an expert committee when necessary. This version was tested on 21 patients to ensure proper understanding. Psychometric characteristics and validity were determined using various measures (sensitivity and specificity via ROC curve and internal consistency via Cronbach's alpha). The correlation between RosaQoL and SF-12 scales was assessed using Pearson correlation coefficients.

**Results:** A total of 531 participants responded to the scale (481 with rosacea and 50 controls). The scale demonstrated excellent sensitivity and specificity (ROC curve, 0.96; 95%CI, 0.92-0.99) and high internal consistency (Cronbach's alpha, 0.96). RosaQoL correlated with SF-12. A higher score on the RosaQoL scale was associated with worse quality of life in all dimensions of the SF-12 scale.

**Conclusions:** The Spanish version of the RosaQoL scale exhibits psychometric characteristics, which are similar to the original scale. Also, the RosaQoL scale is useful to assess the quality of life of patients with rosacea.

© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

DOI of original article: <https://doi.org/10.1016/j.ad.2024.02.014>

\* Corresponding author.

E-mail address: [salleras.m@yahoo.es](mailto:salleras.m@yahoo.es) (M. Salleras Redonnet).

<https://doi.org/10.1016/j.ad.2024.02.035>

0001-7310/© 2024 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: M. Salleras Redonnet, J. del Pozo Losada and M. Ribera Pibernat, [Translated article] Cross-Cultural Validation of the RosaQoL Scale in Spanish Language, ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2024.02.035>

**PALABRAS CLAVE**

Calidad de vida;  
Rosácea;  
Escala;  
Cuestionario;  
Validación y  
adaptación  
transcultural

**Validación transcultural al idioma español de la escala RosaQoL**

**Resumen**

**Introducción:** La rosácea es una enfermedad crónica que afecta negativamente a la calidad de vida y la salud mental de los pacientes. La escala *Rosacea Quality of Life* (RosaQoL) podría ser una herramienta útil para seguir a los pacientes durante el tratamiento de la rosácea, ya que mide el impacto en la calidad de vida y ayuda a adaptar el tratamiento a las necesidades del paciente. Es una escala validada, que se cumplimenta en pocos minutos.

**Materiales y métodos:** Se realizó la traducción y retrotraducción de la escala original, por parte de dos traductores nativos, con el consejo de un comité de expertos cuando fue necesario. Esta versión fue testada en 21 pacientes para comprobar la correcta comprensión. Las características psicométricas y su validez se determinaron utilizando varias medidas (sensibilidad y especificidad mediante curva ROC y consistencia interna por alfa de Cronbach). La correlación entre escalas RosaQoL y SF-12 se realizó mediante coeficientes de correlación de Pearson.

**Resultados:** Un total de 531 participantes respondieron a la escala (481 con rosácea y 50 controles). La escala presentó una excelente sensibilidad y especificidad (curva ROC: 0,96; IC 95%: 0,92-0,99) y una elevada correlación interna (alfa de Cronbach: 0,96). La escala RosaQoL se correlacionó con la SF-12. Una mayor puntuación en la escala RosaQoL se asoció con una peor calidad de vida en todas las dimensiones de la escala SF-12.

**Conclusiones:** La versión española de la escala RosaQoL presenta características psicométricas similares a la escala original, y es útil para evaluar la calidad de vida en los pacientes con rosácea.

© 2024 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (<http://creativecommons.org/licencias/by-nc-nd/4.0/>).

**Introduction**

Rosacea is a chronic skin disease that can also damage the eyes. It typically occurs in middle-aged and older adults with fair skin, especially women. Symptoms include redness, papules, and pustules, and in some patients, thickening and fibrosis of the skin, known as phyma.<sup>1</sup>

Rosacea negatively impacts the patients' quality of life and mental health due to the presence of erythema and facial lesions that severely alter self-image and self-esteem.<sup>2,3</sup>

Health-related quality of life (HRQoL) measurement tools aim to objectively evaluate how a certain disease affects the life of an individual. These questionnaires offer insights into the impact of the disease on overall quality of life or specific areas, such as functionality, emotions, etc.<sup>4</sup>.

HRQoL measurement can be done in 2 ways: using generic instruments that assess quality of life globally, such as the SF-12 questionnaire,<sup>5</sup> and specific instruments to deal with problems associated with particular disorders, patient types, or functional areas,<sup>6,7</sup> such as the Dermatology Life Quality Index [DLQI]<sup>8</sup> or the SKINDEX-29,<sup>9</sup> both validated in Spanish language).

The SF-12 scale, widely used in research, has been associated with specific scales such as the DLQI in atopic dermatitis.<sup>10</sup> However, these generic scales may not adequately capture the impact of certain diseases like rosacea. The Rosacea Quality of Life (RosaQoL) scale—which is specific to rosacea—is available in English and measures the impact of its symptoms on quality of life, being more precise than generalist scales.<sup>11</sup> Having a validated tool in Spanish will allow for assessing the impact on the patient's quality of life, and individualizing treatment effectively.<sup>4,5</sup>

The objectives of this study are: 1) to validate and culturally adapt the RosaQoL scale into Spanish and 2) to analyze the correlation between the RosaQoL scale and the SF-12 scale.

**Materials and methods**

**Study design**

The study was conducted from August through December 2021 after being approved by *Hospital Universitario Sagrat Cor de Barcelona* (Barcelona, Spain) Research and Ethics Committee, and consisted of the translation and cultural adaptation of the RosaQoL scale into Spanish, following the 5 stages indicated in international literature<sup>12–14</sup>: 1) direct translation of the original questionnaire into Spanish by, at least, 2 bilingual translators independently; 2) synthesis and resolution of any discrepancies in the translations; 3) back-translation into the original language by, at least, 2 independent translators who were blinded to the original version; 4) review by an expert committee, consisting of the 3 study coordinators recognized as Key Opinion Leaders in rosacea, to ensure semantic, idiomatic, cultural, and conceptual equivalence; and 5) pilot testing of the translated questionnaire with 21 subjects (7 healthy controls, 2 patients with rosacea, and 12 patients with various dermatological conditions), similar to the target population.

To make sure that the timing associated with response did not influence the result, a test-retest was conducted through which a group of 10 patients completed the scale yet again within 1-2 days of the initial visit. Additionally, to analyze discrimination between cases and controls, a group of 50 subjects without rosacea (controls) completed the scale

117 too. At the end of this phase, a final version of the RosaQoL  
118 questionnaire was ready for validation.

119 In a 2<sup>nd</sup> phase, a total of 481 patients completed the  
120 RosaQoL and SF-12 scales for questionnaire validation pur-  
121 poses.

122 To assess sensitivity to change, the same patients com-  
123 pleted both scales again 3 months later.

## 124 Patients

125 Cultural adaptation to Spanish was performed with 531 adult  
126 participants attending 17 dermatology clinics in Spain. The  
127 sample consisted of 481 participants with varying severity of  
128 rosacea based on the Investigator Global Assessment (IGA)  
129 scale<sup>15</sup> (cases) and 50 healthy participants (controls).

## 130 RosaQoL questionnaire

131 The RosaQoL questionnaire is available in English and mea-  
132 sures the impact of the disorder and its symptoms on quality  
133 of life, being more precise than generalist scales as it is  
134 specific to rosacea-related quality of life.<sup>11</sup>

135 It is a self-administered tool developed from the  
136 SKINDEX-29 questionnaire consisting of 21 items categorized  
137 into 3 dimensions or domains: symptoms (7 items), function-  
138 ality (3 items), and emotional state (11 items). Each item  
139 has a response scale with 5 possible options, being 0: never;  
140 1: rarely; 2: sometimes; 3: often; and 4: always.<sup>11</sup>

## 141 SF-12 questionnaire

142 The SF-12 health questionnaire is available in Spanish and  
143 measures 8 different aspects of HRQoL.<sup>16,17</sup>

144 The SF-12 scale is a self-administered tool developed  
145 from the SF-36 scale consisting of 12 items categorized  
146 into 8 different dimensions or domains: physical function (2  
147 items), physical role (2 items), bodily pain (1 item), general  
148 health (1 item), vitality (1 item), emotional role (2 items),  
149 social function (1 item), and mental health (2 items).<sup>16</sup>

## IGA scale

150 The IGA scale is an ordinal scale with 5 categories that eval-  
151 uate the severity of lesions. Classification goes from 0 (no  
152 inflammatory lesions or erythema) up to 4 (intense erythema  
153 and/or numerous papules and pustules).<sup>15</sup>

## Statistical analysis

154 Data analysis was performed using the SAS System version  
155 9.4 statistical package (SAS Institute Inc., Cary, North Car-  
156 olina, United States).

157 The questionnaire will be considered discriminative  
158 the closer the area under the ROC (Receiver Operating  
159 Characteristic) curve is to a value of 1.00.<sup>18</sup> Both the  
160 sensitivity and specificity rates of the questionnaire were  
161 evaluated using Youden's criterion,<sup>19</sup> and the internal  
162 consistency reliability of the questionnaire was measured  
163 using Cronbach's alpha coefficient.<sup>20</sup> Following the criterion  
164 recommended by George and Mallery,<sup>21</sup> a Cronbach's alpha  
165 coefficient  $\geq 0.90$  indicates excellent internal consistency.  
166 To evaluate test-retest reliability, the method proposed  
167 by Bland and Altman<sup>22</sup> and the intraclass correlation  
168 coefficient proposed by Shrout and Fleiss<sup>23</sup> were used. An  
169 intraclass correlation coefficient  $> 0.90$  indicates high reli-  
170 ability of the questionnaire.<sup>24</sup> Convergence analysis between  
171 the RosaQoL scale and the more general SF-12 scale was  
172  
173

Table 1 Items of the RosaQoL Questionnaire.

How often have you identified yourself with any of these statements over the past 4 weeks?

1	I worry that my rosacea could be severe
2	My rosacea burns or itches
3	I worry about scarring from my rosacea
4	I worry that my rosacea might get worse
5	I worry about the side effects associated with rosacea drugs
6	My rosacea is irritated
7	My rosacea embarrasses me
8	I am frustrated with my rosacea
9	My rosacea makes my skin sensitive
10	I am annoyed by my rosacea
11	I am bothered by the look of my skin (redness, spots)
12	My rosacea makes me feel self-conscious
13	I try to cover my rosacea (with makeup)
14	I am bothered by the persistence/recurrence of my rosacea
15	I avoid certain foods and drinks due to my rosacea
16	My skin looks bumpy (uneven, not smooth, irregular)
17	My skin gets red
18	My skin gets easily irritated (cosmetics, aftershave lotions, makeup removers)
19	My eyes bother me (they feel dry or gritty)
20	I think about my rosacea
21	I avoid certain environments (heat, humidity, cold) due to my rosacea

**Table 2** Severity of rosacea based on the IGA scale at initial visit (cases).

Severity of rosacea	n	% Valid
IGA 0	9	2.16
IGA 1	110	26.38
IGA 2	185	44.36
IGA 3	97	23.26
IGA 4	16	3.84
Missing	64	0.00
Total	481	100.00

obtained using Pearson correlation coefficient (results between 0.4 and 0.7 were considered satisfactory).<sup>25</sup>

## Results

The translated RosaQoL questionnaire (Table 1) was submitted to 531 participants with a mean age of 47 years (SD, 13.4 [95%CI, 45.8-48.1]), 71 of whom (n = 369) were women and 29% (n = 151), men. Among those with rosacea, the papulopustular type was the most common, representing 65.9% of the cases.

According to the IGA scale, IGA grade 2 was the most common one found in 44.4% of the cases (Table 2).

Statistically significant differences were reported between men and women in the overall score of the RosaQoL questionnaire, as well as in each of the 3 dimensions of the scale (symptoms, functionality, and emotional state;  $p < 0.001$ ) (Table 3), although these differences were non statistically significant when analyzed by age (Table 4).

No significant differences were found in the RosaQoL score between the control group (healthy patients [n = 50], mean overall score, 43.5 [SD, 13.7]) and the patient group ([n = 468], mean overall score, 47.3 [SD, 13.3];  $p = 0.052$ ).

Similarly, the score obtained in RosaQoL was higher in more severe grades of rosacea, with a greater impact being reported in the symptomatology dimension (Figure 1).

The internal consistency method, based on Cronbach's alpha, estimates the reliability of a measurement instrument through a set of items expected to measure the same construct or theoretical dimension. Cronbach's alpha value evaluated across all questionnaires was 0.96, which is consistent with the general criterion recommended by George and Mallery<sup>21</sup>, where values  $\geq 0.9$  are indicative of high internal consistency.

When each item was individually removed from the scale, no improvement in Cronbach's alpha was obtained. Therefore, it is established that no item is prone to elimination. The questionnaire statistical power to discriminate cases using the ROC curve yielded an area under the curve (AUC) of 0.96 (95%CI, 0.92-0.99). Considering that values  $> 0.9$  indicate high discriminative power, we can say that the questionnaire has a high capacity to detect cases.

The evaluation of sensitivity and specificity using Youden's criterion yielded a cutoff in the RosaQoL score  $> 1.476$ , thus providing the questionnaire with high sensitivity, with a value of 0.99, and a specificity to detect cases of 0.85. For this cutoff, 425 true positives, 43 true negatives, 7 false positives, and 3 false negatives were reported.

The Varimax rotated component matrix for 3 factors contributes to the validation of the scale construct, showing that items tend to group into the functional, emotional, and symptomatic factors proposed in the original scale<sup>26</sup> (Table 5).

**Table 3** Differences in the RosaQoLquestionnaire scores at initial visit by gender.


	N	Mean (SD)	p-value
<i>Emotional dimension</i>			
Men	137	2.73 (1.16)	0.00010*
Women	332	3.14 (0.98)	
Missing	9	3.41 (0.77)	
Overall	478	3.03 (1.05)	
<i>Symptomatology dimension</i>			
Men	137	2.75 (1.00)	0.00000*
Women	332	3.23 (0.88)	
Missing	9	3.54 (0.46)	
Overall	478	3.10 (0.94)	
<i>Functional dimension</i>			
Men	137	2.04 (1.04)	0.00000*
Women	332	2.91 (1.09)	
Missing	9	3.26 (1.08)	
Overall	478	2.67 (1.15)	
<i>Overall RosaQoL score</i>			
Men	137	2.64 (1.02)	0.00000*
Women	332	3.14 (0.89)	
Missing	9	3.43 (0.63)	
Overall	478	3.00 (0.95)	

\* Statistically significant difference.

**Table 4** Results of the RosaQoL Questionnaire scores by age groups (cases only).

	Mean score (SD)			
	Overall	Emotional dimension	Symptomatology dimension	Functional dimension
18 to 35 years (n = 97)	2.92 (0.99)	2.93 (1.09)	3.03 (0.97)	2.64 (1.14)
36 to 60 years (n = 297)	3.04 (0.93)	3.08 (1.03)	3.14 (0.91)	2.69 (1.14)
> 60 years (n = 71)	2.84 (1.00)	2.86 (1.07)	2.94 (1.04)	2.52 (1.20)
Missing (n = 13)	3.51 (0.64)	3.50 (0.72)	3.67 (0.58)	3.13 (1.06)
Total (n = 478)	3.00 (0.95)	3.03 (1.05)	3.10 (0.94)	2.67 (1.15)

p-value not significant for all age groups.



**Figure 1** Impact of various RosaQoL dimensions based on the severity of rosacea measured by IGA. Significant p-values for all dimensions (p = 0.0000 for all dimensions except for the functional dimension where p = 0.00631). V0: initial visit.

225 All the items of the questionnaire are categorized as  
 226 in the original questionnaire, except for slight discrepan-  
 227 cies in 4 of them. Item #11 ‘‘I am bothered by the look of  
 228 my skin (redness, spots)’’ and item #14 ‘‘I am bothered by  
 229 the persistence/recurrence of my rosacea,’’ which in the  
 230 original scale are grouped in the emotional dimension and  
 231 seem to have a slightly more specific weight in the symp-  
 232 tomatic dimension in the Spanish version. Although item  
 233 #16 ‘‘My skin looks bumpy (uneven, not smooth, irregular)’’  
 234 should be represented in the symptomatic dimension, it is  
 235 somehow better represented in the emotional one. Finally,  
 236 although item #19 ‘‘My eyes bother me (I can feel how  
 237 dry or gritty they are),’’ should be better represented in  
 238 the symptomatic dimension, it was better represented in  
 239 the functional one. Since the specific weight difference of  
 240 these 4 items was minimal, we decided to maintain the  
 241 original dimension classification for comparative evaluation  
 242 purposes with other versions of the scale.

243 When analyzing the correlation between the RosaQoL  
 244 scale and the more generalist SF-12 scale, most studied  
 245 correlations were statistically significant and entirely  
 246 negative. A higher score on the RosaQoL scale in any  
 247 dimension (whether functional, emotional, or symptomatic)  
 248 is associated with a worse quality of life in all dimensions  
 249 of the SF-12 scale (Table 6).

250 The temporal reliability of the questionnaire was con-  
 251 firmed through the test-retest method, as no discrepan-  
 252 cies were detected over time between patients’ responses.

253 To evaluate sensitivity to change, a follow-up visit was  
 254 conducted 3 months after the start of the study, when  
 255 rosacea patients were asked to complete both the RosaQoL  
 256 and SF-12 questionnaires again. In most calculated cor-  
 257 relations, a statistically significant negative correlation was  
 258 reported. A greater increase in the RosaQoL scale and all its  
 259 dimensions (functional, emotional, and symptomatic) was  
 260 associated with a worse progression of quality of life in all



**Table 5** Rotated component matrix of the varimax factor model for the RosaQoL questionnaire (cases only).

Questionnaire item	Question	Emotional	Symptomatic	Functional
Item #1	I worry that my rosacea could be severe	0.73		
Item #3	I worry about scarring from my rosacea	0.76		
Item #4	I worry that my rosacea might get worse	0.65		
Item #5	I worry about the side effects associated with rosacea drugs	0.67		
Item #7	My rosacea embarrasses me	0.72		
Item #8	I am frustrated with my rosacea	0.74		
Item #10	I am annoyed by my rosacea	0.65		
Item #11 <sup>a</sup>	I am bothered by the look of my skin (redness, spots)	0.58	<b>0.64</b>	
Item #12	My rosacea makes me feel self-conscious	0.66		
Item #14 <sup>a</sup>	I am bothered by the persistence/recurrence of my rosacea	0.58	<b>0.63</b>	
Item #20	I think about my rosacea	0.62		
Item #2	My rosacea burns or itches		0.47	
Item #6	My rosacea is irritated		0.71	
Item #9	My rosacea makes my skin sensitive		0.74	
Item #16 <sup>a</sup>	My skin looks bumpy (uneven, not smooth, irregular)	0.48	0.42	
Item #17	My skin gets red		0.82	
Item #18	My skin gets easily irritated (cosmetics, aftershave lotions, makeup removers)		0.73	
Item #19 <sup>a</sup>	My eyes bother me (they feel dry or gritty)		0.26	<b>0.54</b>
Item #13	I try to cover my rosacea (with makeup)			0.53
Item #15	I avoid certain foods and drinks due to my rosacea			0.79
Item #21	I avoid certain environments (heat, humidity, cold) due to my rosacea			0.77

Figures in bold show the results of the factor analysis in the dimension in which it is categorized within the Spanish scale.

Figures in italics show the results of the factor analysis in the dimension it occupied in the original scale.

<sup>a</sup> Item with discrepancy in dimension classification vs the original scale.

261 dimensions of the SF-12 scale. This same correlation was  
262 also seen when analyzed by age group and disease severity.

## 263 Discussion

264 To consider a scale valid as an instrument for measuring  
265 HRQoL, a simple translation is not sufficient; rather, a series  
266 of structured and guided steps are necessary.<sup>13</sup> To make  
267 sure that the reliability and validity requirements of such  
268 tools are met, the measurement properties of the translated  
269 version in a population need to be evaluated with similar  
270 characteristics and then submitted to a validation process.<sup>25</sup>

271 The study of measurement properties demonstrates that  
272 the Spanish-translated and culturally adapted version of the  
273 RosaQoL questionnaire allows us, like the original version,  
to obtain statistically significant differences between the

274 healthy population and the population with rosacea. The  
275 level of impact on the RosaQoL scale in all dimensions was  
276 directly proportional to the severity of rosacea, with the  
277 highest degree of impact being reported in the symptoma-  
278 tology dimension.

279 Nicholson et al.<sup>11</sup> highlighted the validity of RosaQoL in  
280 discriminating rosacea patients vs the SKINDEX-29. In its  
281 original version, the specific RosaQoL scale showed a higher  
282 response level at 4-6 months vs the SKINDEX-29 for the total  
283 score in patients reporting improvement in their rosacea,  
284 showing greater specificity.

285 The reliability study of the RosaQoL questionnaire  
286 demonstrates that the tool has a high degree of internal  
287 consistency, obtaining a Cronbach's alpha value of 0.96, and  
288 that its discriminative power to detect cases is extremely  
289 high, obtaining a ROC AUC score of 0.96.

**Table 6** Correlation between the RosaQoL and SF-12 scales.

	Pearson correlation coefficients									
	Physical health SF-12	Mental health SF-12	Physical function SF-12	Physical role SF-12	Bodily pain SF-12	General health SF-12	Vitality SF-12	Emotional role SF-12	Social function SF-12	Mental health SF-12
<i>Emotional Dimension (RosaQoL)</i>										
Pearson correlation	-0.03553	-0.33318	-0.11879	-0.04632	-0.19839	-0.17693	-0.12947	-0.2349	-0.28287	-0.36157
Sig.	<b>0.471</b>	< 0.0001	0.0146	<b>0.3425</b>	< 0.0001	0.0003	0.0077	< 0.0001	< 0.0001	< 0.0001
N	414	414	422	422	418	423	423	422	422	423
<i>Symptomatology Dimension (RosaQoL)</i>										
Pearson correlation	-0.07726	-0.29001	-0.13782	-0.08834	-0.19843	-0.17091	-0.13874	-0.20142	-0.2995	-0.30055
Sig.	<b>0.1165</b>	< 0.0001	0.0046	<b>0.0699</b>	< 0.0001	0.0004	0.0043	< 0.0001	< 0.0001	< 0.0001
N	414	414	422	422	418	423	423	422	422	423
<i>Functional Dimension (RosaQoL)</i>										
Pearson correlation	-0.04349	-0.32742	-0.10016	-0.16885	-0.21872	-0.08485	-0.16456	-0.26691	-0.31037	-0.30137
Sig.	<b>0.3774</b>	< 0.0001	0.0397	0.0005	< 0.0001	<b>0.0813</b>	0.0007	< 0.0001	< 0.0001	< 0.0001
N	414	414	422	422	418	423	423	422	422	423
<i>Overall RosaQoL score</i>										
Pearson correlation	-0.05504	-0.3571	-0.13555	-0.08981	-0.22579	-0.17785	-0.15483	-0.25805	-0.32736	-0.37258
Sig.	<b>0.2639</b>	< 0.0001	0.0053	<b>0.0653</b>	< 0.0001	0.0002	0.0014	< 0.0001	< 0.0001	< 0.0001
N	414	414	422	422	418	423	423	422	422	423

Figures in bold show statistically non-significant correlations.

Reproducibility is one of the important points we should consider when evaluating a tool for measuring HRQoL. To assess reproducibility, it is checked whether similar scores can be obtained when applied in 2 different points in time to the same population by the same evaluators using the exact same method. Since it is important to avoid the “learning effect,” the time between the initial test and the retest should not be too long.<sup>27</sup> In our study, the score obtained with the RosaQoL questionnaire does not vary significantly between the test and retest results of the same patient (interval of 1 to 2 days). Our test-retest results show a very high correlation between both tests in the 3 dimensions of the questionnaire, indicating a high degree of reliability.

The construct validity study through factor analysis showed that the items of the RosaQoL scale tend to group based on the functional, emotional, and symptomatic dimensions, as in the original version of the scale, and that the items that make up each one of them tend to group consistently in each dimension.

Our study also analyzed the convergence (“correlation”) between the RosaQoL scale and the more generalist SF-12 scale and found that it was positive, evidencing that the scales are conceptually congruent or similar:<sup>25</sup> higher increases in the RosaQoL scale and all its sub-dimensions (functional, emotional, and symptomatic) were associated with worse quality of life in all dimensions of the SF-12 scale.

## Conclusions

The RosaQoL scale, adapted to Spanish, has proven to be a valid, sensitive, and reliable tool for measuring quality of life, in all its dimensions (symptoms, functionality, and emotional state) among the Spanish population with rosacea. Results indicate that the greater the severity of rosacea, the greater the impact on quality of life, with the dimensions of symptomatology and emotional state being the most affected ones, especially in women.

## Conflicts of interest

This project has received funding and support from Laboratorios Galderma S.A.U. Dr. Salleras and Dr. Pozo declared no conflicts of interest whatsoever. Dr. Ribera received grants and fees related to research, consulting, and training from the following companies: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Gebro Pharma, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Pierre-Fabre, Sandoz, SKB, and UCB.

## Acknowledgements

We wish to thank all group participants for their collaboration while working on this manuscript, Laboratorios Galderma S.A.U. for funding the project, and CRO Crossdata for their advice while working on the project and writing this article.

## References

1. Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, et al. Standard classification and pathophysiology of rosacea:

The 2017 update by the National Rosacea Society Expert Committee. *J Am Acad Dermatol.* 2018;78:148–55. 343  
 2. Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. *J Am Acad Dermatol.* 2014;71:973–80. 344  
 3. Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: Effects of demographic and clinical characteristics and various treatment modalities. *Br J Dermatol.* 2010;163:719–25. 345  
 4. Finlay AY. Quality of life indices. *Indian J Dermatol Venereol Leprol.* 2004;70:143–8. 346  
 5. Ware JJ, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care.* 1996;34:220–33. 347  
 6. Wells GA, Russell AS, Haraoui B, Bissonnette R, Ware CF. Validity of quality of life measurement tools—from generic to disease-specific. *J Rheumatol Suppl.* 2011;88:2–6. 348  
 7. Jones-caballero M, Peñas PF. Calidad de vida (II). Calidad de vida en Dermatología. *Actas Dermosifiliogr.* 2002;93:481–9. 349  
 8. García de Tiedra A, Mercadal J, Badía X, Mascaró JM, Herdman M. LR. Adaptación transcultural al español del cuestionario Dermatology Life Quality Index (DLQI): el índice de calidad de vida en Dermatología. *Actas Dermosifiliogr.* 1998;89:692–700. 350  
 9. Jones-Caballero M, Peñas PF, García-Díez A, Chren MM, Badía X. [The Spanish version of Skindex-29 An instrument for measuring quality of life in patients with cutaneous diseases]. *Med Clin (Barc).* 2002;118:5–9. 351  
 10. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in Adults. *J Invest Dermatol.* 2019;139:2090–7. 352  
 11. Nicholson K, Abramova L, Chren MM, Yeung J, Chon SY, Chen SC. A pilot quality-of-life instrument for acne rosacea. *J Am Acad Dermatol.* 2007;57:213–21. 353  
 12. Arafat SMY. Cross Cultural Adaptation & Psychometric Validation of Instruments: Step-wise Description. *Int J Psychiatry.* 2016;1:1–4. 354  
 13. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. *Spine (Phila Pa 1976).* 2000;25:3186–91. 355  
 14. Ramada-Rodilla JM, Serra-Pujadas C, Delclós-Clanchet GL. Adaptación cultural y validación de cuestionarios de salud: Revisión y recomendaciones metodológicas. *Salud Publica Mex.* 2013;55:57–66. 356  
 15. Webster G, Schaller M, Tan J, Jackson JM, Kerrouche N, Schäfer G. Defining treatment success in rosacea as ‘clear’ may provide multiple patient benefits: results of a pooled analysis. *J Dermatolog Treat.* 2017;28:469–74. 357  
 16. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project International Quality of Life Assessment. *J Clin Epidemiol.* 1998;51:1171–8. 358  
 17. Schmidt S, Vilagut G, Garin O, Cunillera O, Tresserras R, Bruguat P, et al. Normas de referencia para el Cuestionario de Salud SF-12 versión 2 basadas en población general de Cataluña. *Med Clin (Barc).* 2012;139:613–25. 359  
 18. Cerda J, Cifuentes L. [Using ROC curves in clinical investigation: theoretical and practical issues]. *Rev Chilena Infectol.* 2012;29:138–41. 360  
 19. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. *Biom J.* 2008;50:419–30. 361  
 20. Cronbach LJ. Coefficient alpha and the internal structure of tests. *Psychometrika.* 1951;16:297–334. 362



- 411 21. George DM, Mallery P. SPSS for Windows step by step: A simple 422  
412 guide and reference 11. 0 update. Boston: Allyn & Bacon; 2003. 423  
413 22. Bland JM, Altman DG. Measuring agreement in method compar- 424  
414 ison studies. Stat Methods Med Res. 1999;8:135-60. 425  
415 23. Shrout PE, Fleiss JL. Intraclass correlations: Uses in assessing 426  
416 rater reliability. Psychol Bull. 1979;86:420-8. 427  
417 24. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass 428  
418 Correlation Coefficients for Reliability Research. J Chiropr Med. 429  
419 2016;15:155-63.  
420 25. Luján-Tangarife JA, Cardona-Arias JA. Construcción y validación  
421 de escalas de medición en salud: Revisión de propiedades psi-  
cométricas. Arch Med. 2015;11:1-10.
26. Vallejo PM. El Análisis Factorial en la construcción e  
interpretación de tests, escalas y cuestionarios. Universi-  
dad Pontificia de Comillas; 2011 [accessed 22 Jul 2022].  
Available from: [http://www.upcomillas.es/personal/peter/  
investigacion/AnalisisFactorial.pdf](http://www.upcomillas.es/personal/peter/investigacion/AnalisisFactorial.pdf)
27. García de Yébenes Prous MJ, Rodríguez Salvanés F, Car-  
mona Ortells L. Validation of questionnaires. Reumatol Clin.  
2009;5:171-7.

UNCORRECTED PROOF